-+ 0.00%
-+ 0.00%
-+ 0.00%

Xilio Therapeutics Doses First Patient in Phase 1/2 Trial of XTX501 for Metastatic Lung Cancer

PUBT·10/26/2026 11:30:29
Listen to the news
Xilio Therapeutics Doses First Patient in Phase 1/2 Trial of XTX501 for Metastatic Lung Cancer
  • Xilio Therapeutics dosed the first patient in a Phase 1/2 trial of XTX501 for metastatic non-small cell lung cancer.
  • The trial enrolls patients previously treated with anti-PD(L)-1 therapy.
  • XTX501 combines PD-1 inhibition with masked IL-2, aiming to deliver tumor-selective immune activation while limiting toxicity.
  • Initial Phase 1 data are expected in the fourth quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260730PRIMZONEFULLFEED9852442) on October 26, 2026, and is solely responsible for the information contained therein.